The next-generation KRAS G12C inhibitor MK-1084 showed promising efficacy and safety as a single agent and in combinations ...

DNA methylation, RTK pathway changes, and KRAS amplifications may drive resistance to sotorasib plus panitumumab in KRAS G12C ...

During a live event, Ahmad Tarhini, MD, PhD, moderated a discussion on selection of immunotherapy regimens for patients with ...

A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy ...

Sara M. Tolaney, MD, MPH, shares new data from the ASCENT-04 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer.

Terence M. Williams, MD, PhD, discussed the phase 1 DINOMITE trial of radiation therapy and papaverine in rectal cancer at ...

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

EBC-129 has been granted FDA fast track designation for the treatment of pancreatic ductal adenocarcinoma, paving the way for ...

The FDA has granted clearance to the IND applications for both the therapeutic ( [ 225 Ac]Ac-AKY-1189) and imaging ( [ 64 ...

Ibrahim Aldoss, MD, discusses a post hoc analysis of ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who did not achieve early MRD negativity.

The pivotal AMPLIFY trial aims to support FDA approval of ⁶⁴Cu-SAR-bisPSMA as a best-in-class imaging tool in prostate cancer ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...